Education
About Us
Working with TipRanks
Follow Us
Atea Pharmaceuticals (AVIR)
NASDAQ:AVIR
Top Page
Atea Pharmaceuticals
(NASDAQ:AVIR)
Select Model
Select Model
Rating:58Neutral
Price Target:
$3.50
▲(0.57% Upside)
The score is held back primarily by weak financial performance (zero revenue, sizable losses, and ongoing cash burn). Offsetting this are constructive earnings-call catalysts (Phase III progress and runway through 2027) and improving technical momentum, while valuation remains constrained due to losses and no indicated dividend.
Positive Factors
Strong Financial Position
A robust cash position ensures operational stability and supports long-term strategic initiatives, reducing immediate financial pressure.
Promising HCV Program
Successful trial results indicate strong potential for market-leading treatment, enhancing future revenue prospects and competitive positioning.
Strategic Board Changes
Board changes and share buyback reflect strategic focus on governance and shareholder value, supporting long-term growth and stability.
Negative Factors
Lack of Revenue
Absence of revenue and profitability challenges raise sustainability concerns, limiting financial flexibility and growth potential.
Negative Cash Flow
Ongoing cash burn without revenue generation threatens long-term viability, necessitating strategic shifts to improve cash flow.
Workforce Reduction
Workforce reduction may impact operational capacity and morale, reflecting cost pressures and strategic realignment challenges.
Atea Pharmaceuticals (AVIR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$271.88M
Dividend YieldN/A
Average Volume (3M)424.40K
Price to Earnings (P/E)―
Beta (1Y)0.78
Revenue GrowthN/A
EPS Growth14.33%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.53
Shares Outstanding78,126,790
10 Day Avg. Volume455,210
30 Day Avg. Volume424,396
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.08
Enterprise Value/Market Cap-0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit16.60
Enterprise Value/Ebitda0.64
Forecast
1Y Price Target
$6.00Price Target Upside72.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Atea Pharmaceuticals Business Overview & Revenue Model
Company DescriptionAtea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
How the Company Makes MoneyAtea Pharmaceuticals generates revenue through partnerships, collaborations, and potential future sales of its antiviral therapeutic products. The company has entered into significant partnerships, such as its collaboration with Roche, to fund development and commercialization of its product candidates. Revenue streams may include milestone payments, royalties, and licensing fees associated with these collaborations. Additionally, upon successful approval and commercialization of its drugs, Atea would earn revenue from direct sales of its antiviral therapies.
Atea Pharmaceuticals Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Mar 03, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in the HCV Phase III program, strong financial health, and promising new research findings. Challenges include an increase in R&D expenses and a decrease in interest income. Overall, the sentiment is predominantly positive due to the outweighing highlights.Q3-2025 Updates
Positive Updates
HCV Phase III Program Progress
The global Phase III program for HCV is on track with patient enrollment for the North American trial, CBEYOND, expected to complete next month. Top-line results are anticipated in mid-2026. The Sea Forward trial, outside North America, is also progressing with enrollment completion expected mid-2026 and results by late 2026.
Strong Financial Position
Atea Pharmaceuticals maintains a strong balance sheet with approximately $329.3 million in cash, cash equivalents, and marketable securities, providing financial runway through 2027.
New Research and Pipeline Expansion
Announced new research findings on bemifovir's unique dual mechanism of action against HCV. Additionally, the antiviral hepatitis pipeline is expanding to include hepatitis E, targeting a major unmet medical need in immunocompromised patients.
Positive Data from Liver Meeting 2025
Presented multiple datasets reinforcing the clinical profile of the bemifovir and riluzole regimen for HCV, including predictions of a cure time of seven to eight weeks and no impact from NS5A resistant variants at baseline.
No Drug-Drug Interaction with Acid-Reducing Therapy
Recent data shows no interaction with famotidine and prior data showed no interaction with proton pump inhibitors, a significant differentiator from Epclusa.
Negative Updates
R&D Expenses Increase
Research and development expenses increased in 2025 compared to 2024, primarily due to increased spending in the HCV clinical development program.
Interest Income Decrease
Interest income in Q3 2025 decreased compared to 2024 due to lower investment balances.
Company Guidance
During the call, Atea Pharmaceuticals provided guidance on several key metrics and developments. The company is on track with its global Phase III program for hepatitis C (HCV), expecting to complete patient enrollment for the North American CBEYOND trial next month and anticipate top-line results by mid-2026. The trial outside of North America, C FORWARD, is expected to complete enrollment by mid-2026, with results anticipated by late 2026. Atea maintains a strong balance sheet with approximately $329.3 million in cash, cash equivalents, and marketable securities, providing financial runway through 2027. This financial position supports the funding of the Phase III program and advancement of new HCV and hepatitis E virus programs. Additionally, Atea highlighted the potential differentiation of their HCV regimen with no interactions with acid-reducing therapies and new data indicating a dual mechanism of action for bemifovir.Atea Pharmaceuticals Financial Statement Overview
Summary
Atea Pharmaceuticals demonstrates financial resilience with a strong equity position and cash reserves, but the lack of revenue and profitability challenges are significant. Without a clear path to generating revenue, the company faces sustainability risks, impacting its overall financial health.Income Statement
Atea Pharmaceuticals has experienced a significant decline in revenue since 2021, when it last reported substantial revenues. The company has had zero revenue in recent periods, alongside consistently negative net income, EBIT, and EBITDA. This demonstrates a challenging revenue environment and profitability issues.Balance Sheet
The company maintains a strong equity base relative to its liabilities, with a high equity ratio. However, the absence of revenue and profitability pressures highlights potential risks to its financial stability in the long term.Cash Flow
Atea's cash flow situation is concerning with negative operating and free cash flows over the past two years. While it has substantial cash reserves, the ongoing cash burn raises sustainability questions without revenue generation.| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 351.37M | 48.63M |
| Gross Profit | -5.96M | -83.37M | -70.09M | -62.39M | 184.16M | 10.61M |
| EBITDA | -155.22M | -131.80M | -119.59M | -110.84M | 138.41M | -11.01M |
| Net Income | -147.03M | -168.38M | -135.96M | -115.91M | 121.19M | -10.95M |
Balance Sheet | ||||||
| Total Assets | 342.96M | 464.67M | 594.97M | 666.71M | 772.89M | 863.63M |
| Cash, Cash Equivalents and Short-Term Investments | 329.31M | 454.72M | 578.11M | 646.71M | 764.38M | 850.12M |
| Total Debt | 1.04M | 1.64M | 2.40M | 3.12M | 197.00K | 0.00 |
| Total Liabilities | 27.18M | 25.80M | 39.78M | 26.14M | 62.81M | 315.83M |
| Stockholders Equity | 315.78M | 438.87M | 555.19M | 640.57M | 710.08M | 547.80M |
Cash Flow | ||||||
| Free Cash Flow | -134.21M | -135.50M | -85.39M | -122.92M | -87.01M | 296.71M |
| Operating Cash Flow | -134.21M | -135.50M | -85.39M | -120.98M | -87.00M | 296.73M |
| Investing Cash Flow | 138.83M | 56.10M | 40.30M | -455.41M | -4.00K | -26.00K |
| Financing Cash Flow | -25.75M | 267.00K | 257.00K | 370.00K | 1.47M | 531.75M |
Atea Pharmaceuticals Technical Analysis
Positive
3.48
Price Trends
3.24
Positive
3.21
Positive
3.20
Positive
Market Momentum
0.10
Negative
64.97
Neutral
59.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AVIR, the sentiment is Positive. The current price of 3.48 is above the 20-day moving average (MA) of 3.36, above the 50-day MA of 3.24, and above the 200-day MA of 3.20, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 64.97 is Neutral, neither overbought nor oversold. The STOCH value of 59.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AVIR.
Atea Pharmaceuticals Risk Analysis
Atea Pharmaceuticals disclosed 82 risk factors in its most recent earnings report. Atea Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Atea Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $271.88M | -2.03 | -37.98% | ― | ― | 14.33% | |
55 Neutral | $273.52M | -3.20 | -22.37% | ― | 3.36% | 5.15% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $231.04M | -15.70 | ― | ― | 12.60% | 58.23% | |
42 Neutral | $153.55M | -2.24 | -114.26% | ― | -17.87% | 14.42% | |
42 Neutral | $227.26M | -4.60 | -99.45% | ― | -11.99% | -42.04% |
* Healthcare Sector Average
AVIR
Atea Pharmaceuticals
3.61
0.34
10.40%
CDXS
Codexis
1.68
-2.71
-61.73%
HRTX
Heron Therapeutics
1.27
-0.28
-18.06%
PRQR
ProQR
2.10
-0.32
-13.22%
TLSA
Tiziana Life Sciences
1.48
0.64
76.19%
OABI
OmniAb
1.89
-1.55
-45.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.